Nehal J. Lakhani
Expertise in
17
conditions

Dr. Nehal J. Lakhani

Oncology
The Cancer & Hematology Centers
145 Michigan Street Northeast, Suite 3100, 
Grand Rapids, MI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Referral may be required
Before you request
Expertise in
17
conditions
The Cancer & Hematology Centers
145 Michigan Street Northeast, Suite 3100, 
Grand Rapids, MI 

Overview

Nehal Lakhani is an Oncologist practicing medicine in Grand Rapids, Michigan.

Dr. Lakhani is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Endometrial Cancer, Adult Soft Tissue Sarcoma, and Pleuropulmonary Blastoma.

Dr. Lakhani is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 40 peer reviewed articles and participating in 29 clinical trials. Dr. Lakhani is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MI

Board Certifications

American Board Of Internal Medicine

Fellowships

National Institutes of Health Clinical Center

Hospital Affiliations

Corewell Health Grand Rapids Hospitals
Spectrum Health

Languages Spoken

English
Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

The Cancer & Hematology Centers
145 Michigan Street Northeast, Suite 3100, Grand Rapids, MI 49503
Other Locations
The Cancer & Hematology Centers - Foremost Drive Ste 100
5800 Foremost Drive Southeast, Suite 100, Grand Rapids, MI 49546

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug
Study Drugs: CPI-0209, Irinotecan
Study Phase: Phase 1/Phase 2
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 09, 2026
Intervention Type: Drug
Study Drug: SGN-B7H4V
Study Phase: Phase 1
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Biological
Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody
Study Phase: Phase 1
A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drug: AVID100
Study Phase: Phase 1/Phase 2
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drug: SGN-ALPV
Study Phase: Phase 1
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: SGN-STNV
Study Phase: Phase 1
View 9 Less Clinical Trials

40 Total Publications

Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
Similar Doctors
Expertise in
47
conditions
Dr. Erin M. Pettijohn
Oncology | Hematology Oncology | Hematology
Expertise in
47
conditions
Dr. Erin M. Pettijohn
Oncology | Hematology Oncology | Hematology
Referral may be required
Before you request

The Cancer & Hematology Centers

145 Michigan Street Northeast, Suite 3100, 
Grand Rapids, MI 
 (0.1 miles away)
616-954-9800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erin Pettijohn is an Oncologist and a Hematologist Oncology provider practicing medicine in Grand Rapids, Michigan. Dr. Pettijohn is highly rated in 47 conditions, according to our data. Her clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration. Dr. Pettijohn is board certified in American Board Of Internal Medicine. Dr. Pettijohn is currently accepting new patients.

Expertise in
34
conditions
Dr. Sreenivasa R. Chandana
Oncology | Hematology Oncology | Gastroenterology
Expertise in
34
conditions
Dr. Sreenivasa R. Chandana
Oncology | Hematology Oncology | Gastroenterology
Referral may be required
Before you request

The Cancer & Hematology Centers - Muskegon

6425 Harvey Street, 
Norton Shores, MI 
 (31.1 miles away)
231-737-3469
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Sreenivasa Chandana is an Oncologist and a Hematologist Oncology provider practicing medicine in Norton Shores, Michigan. Dr. Chandana is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Familial Colorectal Cancer, Endoscopy, and Pancreatectomy. Dr. Chandana is board certified in American Board Of Internal Medicine. Dr. Chandana is currently accepting new patients.

Expertise in
26
conditions
Expertise in
26
conditions
Referral required
Before you request

The Cancer & Hematology Centers

710 Kenmoor Avenue Southeast, Suite 200, 
Grand Rapids, MI 
 (7.0 miles away)
616-389-1800
Languages Spoken:
English, Croatian
See accepted insurances
Accepting New Patients

Eric Santos is an Oncologist practicing medicine in Grand Rapids, Michigan. Dr. Santos is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Familial Colorectal Cancer, Pleuropulmonary Blastoma, Colorectal Cancer, and Awake Craniotomy. Dr. Santos is board certified in American Board Of Internal Medicine. Dr. Santos is currently accepting new patients.

Frequently Asked Questions about Dr. Nehal J. Lakhani

How do I make an appointment with Dr. Nehal J. Lakhani?

You can book an appointment with Dr. Nehal J. Lakhani by calling their office at 616-954-9800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nehal J. Lakhani a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nehal J. Lakhani is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nehal J. Lakhani specialize in?

While Dr. Nehal J. Lakhani is a Oncology, they have specific expertise in Lung Cancer, Endometrial Cancer, and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Nehal J. Lakhani participate in research or clinical trials?

Yes. Dr. Nehal J. Lakhani has published 40 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Nehal J. Lakhani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nehal J. Lakhani accept my insurance?

Dr. Nehal J. Lakhani accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 616-954-9800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lakhani's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 78 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile